Elizabeth J. Rahn, Ph.D., M.S.

Affiliations: 
Neurobiology University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
Pain, Cannabinoids, Neuropsychopharmacology, Epigenetics
Google:
"Elizabeth Rahn"
Mean distance: 13.78 (cluster 19)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kennedy AJ, Rahn EJ, Paulukaitis BS, et al. (2016) Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function. Cell Reports
Rahn EJ, Deng L, Thakur GA, et al. (2014) Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Molecular Pain. 10: 27
Rahn EJ, Iannitti T, Donahue RR, et al. (2014) Sex differences in a mouse model of multiple sclerosis: neuropathic pain behavior in females but not males and protection from neurological deficits during proestrus. Biology of Sex Differences. 5: 4
Rahn EJ, Guzman-Karlsson MC, David Sweatt J. (2013) Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory. Neurobiology of Learning and Memory. 105: 133-50
Rahn EJ, Thakur GA, Wood JA, et al. (2011) Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacology, Biochemistry, and Behavior. 98: 493-502
Rahn EJ, Zvonok AM, Makriyannis A, et al. (2010) Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. The Aaps Journal. 12: 147-57
Rahn EJ, Hohmann AG. (2009) Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 713-37
Rahn EJ, Zvonok AM, Thakur GA, et al. (2008) Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. The Journal of Pharmacology and Experimental Therapeutics. 327: 584-91
Rahn EJ, Makriyannis A, Hohmann AG. (2007) Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. British Journal of Pharmacology. 152: 765-77
See more...